The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH.
about
The role of the pharmacist in the selection and use of over-the-counter proton-pump inhibitorsComparator pH study to evaluate the single-dose pharmacodynamics of dual delayed-release dexlansoprazole 60 mg and delayed-release esomeprazole 40 mgPharmacologic properties of proton pump inhibitors.CYP2C19 polymorphism and proton pump inhibitors.Effect of timing of dosing in relation to food intake on the pharmacokinetics of esomeprazole.Review article: the opportunities and benefits of extended acid suppression.Pharmacokinetics and pharmacodynamics of the proton pump inhibitors.Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers.Esomeprazole: potent acid suppression in the treatment of acid-related disorders.Proton Pump Inhibitors Display Antitumor Effects in Barrett's Adenocarcinoma CellsTyrosine Kinase Inhibitors and Proton Pump Inhibitors: An Evaluation of Treatment Options.Intra-gastric pH following single oral administrations of rabeprazole and esomeprazole: double-blind cross-over comparisonPharmacokinetics of rabeprazole granules versus tablets, and the effect of food on the pharmacokinetics of rabeprazole granules in healthy adults-cross-study comparison.Esomeprazole for the treatment of peptic ulcer bleeding.Effect of the proton pump inhibitor esomeprazole on the oral absorption and pharmacokinetics of nilotinib.Intragastric acid suppression and pharmacokinetics of twice-daily esomeprazole: a randomized, three-way crossover study.Esomeprazole 40 mg twice daily in triple therapy and the efficacy of Helicobacter pylori eradication related to CYP2C19 metabolism.Dose-dependent inhibitory effects of proton pump inhibitors on human osteoclastic and osteoblastic cell activity.First-week clinical responses to dexlansoprazole 60 mg and esomeprazole 40 mg for the treatment of grades A and B gastroesophageal reflux disease.Plasma concentration of rabeprazole after 8-week administration in gastroesophageal reflux disease patients and intragastric pH elevation.Effect of CYP2C19 genetic polymorphism on pharmacokinetics and pharmacodynamics of a new proton pump inhibitor, ilaprazole.
P2860
Q26866168-7EDC66E6-F951-42B6-99B9-C63A15F1F440Q35304679-FAEABA96-0573-4E27-B344-2AEBB97A2AC6Q35572512-C6979164-0421-47FA-B1FE-C08EAB411454Q35831792-D8603CD7-A88E-4D87-A330-A56BD87D341CQ36024697-87577767-1A0A-4250-87C3-E752699ECB4FQ36478875-0733FD09-0274-4692-9D33-FAEB4A3D18EAQ36542670-2DB0FB58-51FF-42A8-B5CE-3B09E7E55B72Q36808048-DBE3F051-2FB2-41C9-8B76-33B9393910F2Q37755220-A221A4DC-97CA-4FB5-9B48-F45000EBEC03Q38727019-B8E73D57-AB6A-476B-BD37-7D33C74364CBQ39013343-46782093-9143-4298-8A9E-F4B2699DF866Q39014361-94196DB0-2D34-49BA-916B-099E1D754C4EQ39809735-977AD89D-E994-4981-872E-25B8D7EB827AQ42792216-602647A5-252E-4C32-8E27-F07453BC8B0AQ43055360-488733DD-EDD8-4D51-94A6-5D7E55B01A06Q45009904-E6F8DCBD-B8B1-42B8-8BE3-2A5BD6ADC651Q45250885-B9656343-AD51-4A79-9AEB-23BDE14796D7Q45773103-33654C79-23D3-4053-B47B-BFB5639AC4B8Q47110692-8C8431A4-6078-4393-951B-98EDD5E4B096Q50680833-A24AA428-7437-41A5-9800-01C498B742CCQ51461774-1AAFEFE1-CDAF-40A1-B2CB-0E885580B5C5
P2860
The effect of the area under the plasma concentration vs time curve and the maximum plasma concentration of esomeprazole on intragastric pH.
description
2002 nî lūn-bûn
@nan
2002年の論文
@ja
2002年学术文章
@wuu
2002年学术文章
@zh
2002年学术文章
@zh-cn
2002年学术文章
@zh-hans
2002年学术文章
@zh-my
2002年学术文章
@zh-sg
2002年學術文章
@yue
2002年學術文章
@zh-hant
name
The effect of the area under t ...... omeprazole on intragastric pH.
@en
The effect of the area under t ...... omeprazole on intragastric pH.
@nl
type
label
The effect of the area under t ...... omeprazole on intragastric pH.
@en
The effect of the area under t ...... omeprazole on intragastric pH.
@nl
prefLabel
The effect of the area under t ...... omeprazole on intragastric pH.
@en
The effect of the area under t ...... omeprazole on intragastric pH.
@nl
P2093
P1476
The effect of the area under t ...... omeprazole on intragastric pH.
@en
P2093
Göran Hasselgren
Mohammed Hassan-Alin
Ola Junghard
P2888
P304
P356
10.1007/S00228-002-0502-1
P577
2002-09-03T00:00:00Z